Literature DB >> 18936709

BPH gene expression profile associated to prostate gland volume.

Aurelien Descazeaud1, Mark A Rubin, Matthias Hofer, Sunita Setlur, Nathalie Nikolaief, Francis Vacherot, Pascale Soyeux, Laurence Kheuang, Claude C Abbou, Yves Allory, Alexandre de la Taille.   

Abstract

The aim of the current study was to analyze gene expression profiles in benign prostatic hyperplasia and to compare them with phenotypic properties. Thirty-seven specimens of benign prostatic hyperplasia were obtained from symptomatic patients undergoing surgery. RNA was extracted and hybridized to Affymetrix Chips containing 54,000 gene expression probes. Gene expression profiles were analyzed using cluster, TreeView, and significance analysis of microarrays softwares. In an initial unsupervised analysis, our 37 samples clustered hierarchically in 2 groups of 18 and 19 samples, respectively. Five clinical parameters were statistically different between the 2 groups: in group 1 compared with group 2, patients had larger prostate glands, had higher prostate specific antigen levels, were more likely to be treated by alpha blockers, to be operated by prostatectomy, and to have major irritative symptoms. The sole independent parameter associated with this dichotome clustering, however, was the prostate gland volume. Therefore, the role of prostate volume was explored in a supervised analysis. Gene expression of prostate glands <60 mL and >60 mL were compared using significance analysis of microarrays and 227 genes were found differentially expressed between the 2 groups (>2 change and false discovery rate of <5%). Several specific pathways including growth factors genes, cell cycle genes, apoptose genes, inflammation genes, and androgen regulated genes, displayed major differences between small and large prostate glands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936709      PMCID: PMC2822796          DOI: 10.1097/PDM.0b013e31816f6352

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  31 in total

1.  Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.

Authors:  Dina G Tiniakos; Dionisios Mitropoulos; Aspasia Kyroudi-Voulgari; Kiriaki Soura; Christos Kittas
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

2.  Distribution of 15 human kallikreins in tissues and biological fluids.

Authors:  Julie L V Shaw; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2007-06-15       Impact factor: 8.327

3.  mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy.

Authors:  Andreas Scorilas; Alkiviades K Gregorakis
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

4.  Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.

Authors:  Claudio Festuccia; Paola Muzi; Giovanni Luca Gravina; Danilo Millimaggi; Silvia Speca; Vincenza Dolo; Enrico Ricevuto; Carlo Vicentini; Mauro Bologna
Journal:  Int J Oncol       Date:  2007-01       Impact factor: 5.650

5.  Benign prostatic hyperplasia: does prostate size matter?

Authors:  J Curtis Nickel
Journal:  Rev Urol       Date:  2003

6.  Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.

Authors:  N Kyprianou; C M Benning
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.

Authors:  Jun Luo; Thomas Dunn; Charles Ewing; Jurga Sauvageot; Yidong Chen; Jeffrey Trent; William Isaacs
Journal:  Prostate       Date:  2002-05-15       Impact factor: 4.104

8.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters.

Authors:  M E Harper; E Glynne-Jones; L Goddard; D W Wilson; S S Matenhelia; I G Conn; W B Peeling; K Griffiths
Journal:  Prostate       Date:  1992       Impact factor: 4.104

10.  Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.

Authors:  Gaëlle Fromont; Laurent Chene; Alain Latil; Ivan Bieche; Michel Vidaud; Guy Vallancien; Philippe Mangin; Georges Fournier; Pierre Validire; Olivier Cussenot
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

View more
  9 in total

Review 1.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

2.  Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures.

Authors:  Stéphane Larré; Philippe Camparo; Eva Comperat; Delphine Boulbés; Mohammed Haddoum; Sylvain Baulande; Pascal Soularue; Pierre Costa; Olivier Cussenot
Journal:  Asian J Androl       Date:  2011-12-26       Impact factor: 3.285

Review 3.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

Review 4.  Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.

Authors:  Anne K Mongiu; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 5.  The many ways to make a luminal cell and a prostate cancer cell.

Authors:  Douglas W Strand; Andrew S Goldstein
Journal:  Endocr Relat Cancer       Date:  2015-08-25       Impact factor: 5.678

6.  Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.

Authors:  Feng Li; Laura E Pascal; Ke Wang; Yibin Zhou; Goundappa K Balasubramani; Katherine J O'Malley; Rajiv Dhir; Kai He; Donna Stolz; Donald B DeFranco; Naoki Yoshimura; Joel B Nelson; Tie Chong; Peng Guo; Dalin He; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

7.  Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract.

Authors:  Sridar Chittur; Brian Parr; Geno Marcovici
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-08       Impact factor: 2.629

8.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Authors:  Deli Liu; Jonathan E Shoag; Daniel Poliak; Ramy S Goueli; Vaishali Ravikumar; David Redmond; Aram Vosoughi; Jacqueline Fontugne; Heng Pan; Daniel Lee; Domonique Thomas; Keyan Salari; Zongwei Wang; Alessandro Romanel; Alexis Te; Richard Lee; Bilal Chughtai; Aria F Olumi; Juan Miguel Mosquera; Francesca Demichelis; Olivier Elemento; Mark A Rubin; Andrea Sboner; Christopher E Barbieri
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

9.  IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway.

Authors:  Hua-Cheng Lo; Dah-Shyong Yu; Hong-Wei Gao; Mong-Hsun Tsai; Eric Y Chuang
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.